Cogent Biosciences (COGT) Liabilities and Shareholders Equity (2017 - 2026)

Cogent Biosciences (COGT) has reported Liabilities and Shareholders Equity for 10 consecutive years, with $903.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 218.19% year-over-year to $903.0 million; the TTM figure through Mar 2026 stood at $2.5 billion (up 78.26% YoY), while the FY2025 annual figure was $937.6 million, up 185.94% from the prior year.
• Liabilities and Shareholders Equity retreated to $903.0 million in Q1 2026 per COGT's latest filing, from $937.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $937.6 million in Q4 2025 and bottomed at $206.9 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $410.2 million across 5 years, with a median of $355.4 million in 2023.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity slumped 40.39% — and 2026, when it jumped 218.19%.
• Cogent Biosciences' Liabilities and Shareholders Equity stood at $300.8 million in 2022, then gained by 4.2% to $313.4 million in 2023, then increased by 4.61% to $327.9 million in 2024, then soared by 185.94% to $937.6 million in 2025, then slipped by 3.69% to $903.0 million in 2026.
• Business Quant data shows COGT's Liabilities and Shareholders Equity at $903.0 million in Q1 2026, $937.6 million in Q4 2025, and $425.9 million in Q3 2025.